VistaGen Therapeutics, Inc.

Form 3

August 01, 2011

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement VistaGen Therapeutics, Inc. [VSTA.OB] A Platinum Long Term Growth (Month/Day/Year) VII, LLC 05/13/2011 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 152 WEST 57TH (Check all applicable) STREET. 4TH FLOOR (Street) 6. Individual or Joint/Group __X__ 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting Person NEW YORK. NYÂ 10019 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â Common Stock, par value \$0.001 per share 2,042,862 D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative Security 2. Date Exercisable and 4. 5. **Expiration Date** Securities Underlying Beneficial (Instr. 4) Conversion Ownership (Month/Day/Year) Derivative Security or Exercise Form of Ownership (Instr. 4) Price of Derivative (Instr. 5) Derivative Security:

Edgar Filing: VistaGen Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Common Stock Warrants	05/11/2011	12/31/2013	Common Stock	560,000 (1)	\$ 1.5	D	Â
Common Stock Warrants	05/11/2011	12/31/2013	Common Stock	825,574 (1)	\$ 2.5	D	Â
Common Stock Warrants	05/11/2011	12/31/2013	Common Stock	214,284 (1)	\$ 2.5	D	Â
Convertible Notes	05/11/2011	06/30/2012	Common Stock	3,368,169 (1) (2)	\$ 1.75	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships		
	Director	10% Owner	Officer	Other
Platinum Long Term Growth VII, LLC 152 WEST 57TH STREET 4TH FLOOR NEW YORK. NY 10019	Â	ÂX	Â	Â

Signatures

/s/ OLIVER
JIMENEZ

**Signature of Reporting Person

O8/01/2011

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

that the number of shares of common stock that may be acquired by the holder upon exercise of the warrants or conversion of the notes is limited to the extent necessary to ensure that, following such exercise, the total number of shares of common stock then beneficially owned by the holder does not exceed 9.99 percent of the total number of issued and outstanding shares of common stock, including for such purpose the shares of common stock issuable upon such exercise or conversion, of the Issuer without providing the Issuer with 61 days prior notice thereof.

The common stock warrants and convertible notes provide a limitation on the exercise or conversion of such warrants and notes, such

The formula for determining the number of shares of common stock that may be acquired by the holder upon conversion of the notes is subject to adjustment as a result of, among other factors, future offerings of the securities of the Issuer and the number of the shares of common stock of the Issuer on a modified fully-diluted basis.

Â

Remarks:

This Form 3 is filed by Platinum Long Term Growth VII, LLC (PLTG VII) in respect of securit

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2